Abstract

Purpose Patients with high-grade osteosarcoma undergo several chemotherapy cycles before surgical intervention. Response to chemotherapy, however, is affected by intratumor heterogeneity. In this study, we assessed the ability of a machine learning approach using baseline 18F-fluorodeoxyglucose (18F-FDG) positron emitted tomography (PET) textural features to predict response to chemotherapy in osteosarcoma patients. Materials and Methods This study included 70 osteosarcoma patients who received neoadjuvant chemotherapy. Quantitative characteristics of the tumors were evaluated by standard uptake value (SUV), total lesion glycolysis (TLG), and metabolic tumor volume (MTV). Tumor heterogeneity was evaluated using textural analysis of 18F-FDG PET scan images. Assessments were performed at baseline and after chemotherapy using 18F-FDG PET; 18F-FDG textural features were evaluated using the Chang-Gung Image Texture Analysis toolbox. To predict the chemotherapy response, several features were chosen using the principal component analysis (PCA) feature selection method. Machine learning was performed using linear support vector machine (SVM), random forest, and gradient boost methods. The ability to predict chemotherapy response was evaluated using the area under the receiver operating characteristic curve (AUC). Results AUCs of the baseline 18F-FDG features SUVmax, TLG, MTV, 1st entropy, and gray level co-occurrence matrix entropy were 0.553, 0538, 0.536, 0.538, and 0.543, respectively. However, AUCs of the machine learning features linear SVM, random forest, and gradient boost were 0.72, 0.78, and 0.82, respectively. Conclusion We found that a machine learning approach based on 18F-FDG textural features could predict the chemotherapy response using baseline PET images. This early prediction of the chemotherapy response may aid in determining treatment plans for osteosarcoma patients.

Highlights

  • Osteosarcoma is a malignant tumor that primarily develops in bones of patients between 5 and 25 years of age

  • Osteosarcoma is a type of mesenchymal tumor that frequently metastasizes to the lungs and peripheral bone. erefore, metastatic potential is a key factor in determining the diagnosis and prognosis of osteosarcoma [1, 2]. e introduction of neoadjuvant chemotherapy (NAC) in the treatment of osteosarcoma has led to improved prognosis and enhanced patient survival

  • positron emitted tomography (PET) images in Figure 1 represent patients classified as responders or nonresponders, based on histological findings

Read more

Summary

Introduction

Osteosarcoma is a malignant tumor that primarily develops in bones of patients between 5 and 25 years of age. Osteosarcoma is a type of mesenchymal tumor that frequently metastasizes to the lungs and peripheral bone. Erefore, metastatic potential is a key factor in determining the diagnosis and prognosis of osteosarcoma [1, 2]. E introduction of neoadjuvant chemotherapy (NAC) in the treatment of osteosarcoma has led to improved prognosis and enhanced patient survival. Patient prognosis after combined NAC and surgery is better than after either treatment as monotherapy [3, 4]. Patients with high-grade osteosarcoma have numerous cycles of NAC before surgery. Ine ective NAC can be toxic and may increase resistance to anticancer drugs [5]. Histological assessment of response to NAC can only be performed using resected specimens; response cannot be monitored during the course of NAC

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call